TENX
Tenax Therapeutics, Inc.
Biotechnology
Market Cap$71M
5Y Perf.-99.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TENX vs ATHA
Revenue, margins, valuation, and 5-year total return — side by side.
ATHA
Athira Pharma, Inc.
Biotechnology
Market Cap$17M
5Y Perf.-97.4%
TENX vs ATHA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TENX | ATHA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $71M | $17M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-43M | $-106M |
| Total Debt | $0.00 | $803K |
| Cash & Equiv. | $95M | $69M |
TENX vs ATHA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TENX
ATHA
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Tenax Therapeutics,… (TENX) | 100 | 0.5 | -99.5% |
| Athira Pharma, Inc. (ATHA) | 100 | 2.6 | -97.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TENX vs ATHA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TENX leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TENX
Tenax Therapeutics, Inc.
The Income Pick
TENX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.90
- EPS growth 96.3%
- Lower volatility, beta 0.90, current ratio 20.60x
Best for: income & stability and growth exposure
ATHA
Athira Pharma, Inc.
The Long-Run Compounder
ATHA is the clearest fit if your priority is long-term compounding.
- -97.5% 10Y total return vs TENX's -100.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TENX | 428.0% revenue growth vs ATHA's -10.0% |
| Stability / Safety | TENX | Beta 0.90 vs ATHA's 1.47 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TENX | +124.3% vs ATHA's +70.2% |
| Efficiency (ROA) | TENX | -42.1% ROA vs ATHA's -209.9% |
TENX vs ATHA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2013
Segment breakdown not available.
TENX vs ATHA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTENXLAGGINGATHA
ATHAAthira Pharma, Inc.
0leads
TENXTenax Therapeutics, I…
4leads
6 Total Categories
CATEGORYLEADERvs ATHAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TENX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TENX6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
TENX4/6
Risk & VolatilityBeta, volatility, and downside exposure
TENX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TENX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TENX and ATHA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | TENXTenax Therapeutic… | ATHAAthira Pharma, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$43M | -$102M |
| Net IncomeAfter-tax profit | -$43M | -$106M |
| Free Cash FlowCash after capex | -$26M | -$46M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -110.5% | -3.9% |
TENX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TENX and ATHA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TENXTenax Therapeutic… | ATHAAthira Pharma, In… |
|---|---|---|
| Market CapShares × price | $71M | $17M |
| Enterprise ValueMkt cap + debt − cash | -$24M | -$30M |
| Trailing P/EPrice ÷ TTM EPS | -10.45x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.00x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TENX and ATHA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TENX leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
TENX delivers a -45.0% return on equity — every $100 of shareholder capital generates $-45 in annual profit, vs $-3 for ATHA. On the Piotroski fundamental quality scale (0–9), TENX scores 3/9 vs ATHA's 2/9, reflecting mixed financial health.
| Metric | TENXTenax Therapeutic… | ATHAAthira Pharma, In… |
|---|---|---|
| ROE (TTM)Return on equity | -45.0% | -3.4% |
| ROA (TTM)Return on assets | -42.1% | -2.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -39.0% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$95M | -$68M |
| Cash & Equiv.Liquid assets | $95M | $69M |
| Total DebtShort + long-term debt | $0 | $803,000 |
| Interest CoverageEBIT ÷ Interest expense | -847.57x | — |
TENX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
TENX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATHA five years ago would be worth $240 today (with dividends reinvested), compared to $35 for TENX. Over the past 12 months, TENX leads with a +124.3% total return vs ATHA's +70.2%. The 3-year compound annual growth rate (CAGR) favors TENX at -22.6% vs ATHA's -46.7% — a key indicator of consistent wealth creation.
| Metric | TENXTenax Therapeutic… | ATHAAthira Pharma, In… |
|---|---|---|
| YTD ReturnYear-to-date | +8.8% | -37.6% |
| 1-Year ReturnPast 12 months | +124.3% | +70.2% |
| 3-Year ReturnCumulative with dividends | -53.6% | -84.8% |
| 5-Year ReturnCumulative with dividends | -99.6% | -97.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -97.5% |
| CAGR (3Y)Annualised 3-year return | -22.6% | -46.7% |
TENX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
TENX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TENX is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than ATHA's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TENX currently trades 65.4% from its 52-week high vs ATHA's 51.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TENXTenax Therapeutic… | ATHAAthira Pharma, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 1.47x |
| 52-Week HighHighest price in past year | $18.38 | $8.36 |
| 52-Week LowLowest price in past year | $5.34 | $2.30 |
| % of 52W HighCurrent price vs 52-week peak | +65.4% | +51.9% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 508K | 46K |
TENX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TENXTenax Therapeutic… | ATHAAthira Pharma, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TENX leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallTenax Therapeutics, Inc. (TENX)Leads 4 of 6 categories
Loading custom metrics...
TENX vs ATHA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — TENX or ATHA?
Over the past 5 years, Athira Pharma, Inc.
(ATHA) delivered a total return of -97. 6%, compared to -99. 6% for Tenax Therapeutics, Inc. (TENX). Over 10 years, the gap is even starker: ATHA returned -97. 5% versus TENX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — TENX or ATHA?
By beta (market sensitivity over 5 years), Tenax Therapeutics, Inc.
(TENX) is the lower-risk stock at 0. 90β versus Athira Pharma, Inc. 's 1. 47β — meaning ATHA is approximately 63% more volatile than TENX relative to the S&P 500.
03Which is growing faster — TENX or ATHA?
On earnings-per-share growth, the picture is similar: Tenax Therapeutics, Inc.
grew EPS 96. 3% year-over-year, compared to 2. 0% for Athira Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — TENX or ATHA?
Tenax Therapeutics, Inc.
(TENX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TENX leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — TENX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TENX or ATHA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TENX or ATHA better for a retirement portfolio?
For long-horizon retirement investors, Tenax Therapeutics, Inc.
(TENX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Both have compounded well over 10 years (TENX: -100. 0%, ATHA: -97. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TENX and ATHA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.